hero section gradient
15 handpicked stocks

Earnings Over Headwinds

A carefully selected collection of companies showing exceptional earnings growth despite market challenges. These stocks were handpicked by our analysts for their ability to maintain strong performance even when facing trade tensions and economic uncertainty.

Author avatar

Han Tan | Market Analyst

Published on July 2

Your Basket's Financial Footprint

Summary and investor takeaways for the 'Earnings Over Headwinds' basket based on provided market capitalisation data.

Key Takeaways for Investors:
  • Large-cap dominance generally implies lower volatility and closer tracking of broad-market moves, reducing portfolio downside risk.
  • Use as a core holding for stable exposure rather than a speculative growth position.
  • Expect steady, long-term appreciation rather than rapid, short-term gains; growth likely moderate.
Total Market Cap
  • MSFT: $3.85T

  • LLY: $756.76B

  • COST: $415.48B

  • Other

About This Group of Stocks

1

Our Expert Thinking

When markets worry about tariffs and trade tensions, companies with strong fundamentals often shine through. We've identified businesses that are beating earnings expectations and demonstrating operational excellence despite economic headwinds, suggesting they may be better positioned to weather uncertainty.

2

What You Need to Know

This group includes companies across diverse sectors—from software and pharmaceuticals to industrials and retail. What connects them is their demonstrated ability to maintain profit growth, optimize margins, or leverage subscription-based models that provide stability even when facing challenges.

3

Why These Stocks

Each company in this collection has shown specific signs of resilience, such as beating analyst forecasts, growing recurring revenue, or successfully managing costs. These businesses have the pricing power, operational efficiency, or market positioning to potentially outperform despite macroeconomic headwinds.

Why You'll Want to Watch These Stocks

💪

Beating Expectations When It Matters

Companies in this group are exceeding analyst forecasts by impressive margins—some beating EPS estimates by over 7-9%. These aren't just meeting targets; they're smashing them during uncertain times.

🛡️

Built-In Protection Against Uncertainty

While other stocks may falter when trade tensions rise, these companies have business models specifically designed to weather the storm. Their recurring revenue, pricing power, or operational efficiency provides a defensive buffer.

🔍

Smart Money Is Watching These Closely

Professional investors are increasingly distinguishing between companies that can navigate headwinds versus those that can't. This collection represents businesses that analysts believe have the fundamentals to thrive despite economic noise.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions